NEW YORK (GenomeWeb) – The US Food and Drug Administration has expanded the labeling for Roche's Cobas EGFR Mutation Test v2 as a companion diagnostic that can analyze plasma samples from non-small cell lung cancer patients considering treatment with AstraZeneca's Tagrisso (osimertinib).